Efficacy and Safety of Subcutaneous Garadacimab for the Prophylaxis of Hereditary Angioedema Attacks in Adults and Adolescent Patients with HAE: Results from a Multicenter, Placebo-Controlled Phase 3 Trial

Timothy J Craig ,Gordon Sussman,Isao Ohsawa,Henriette Farkas,Lolis Wieman,Bruce Ritchie,Raffi Tachdjian,Markus Magerl,Iris Jacobs,Henrike Feuersenger,Regina Treudler,Petra Staubach,Avner Reshef,Emel Aygören‐Pürsün ,Michael R Manning ,I Martinez Saguer ,William R Lumry ,Jonathan A Bernstein ,Joshua J Jacobs ,K Kawahata ,Huamin Li ,J D Anderson ,William Yang ,Erik S.g Stroes ,Yoshio Suzuki

doi:10.1016/j.jaci.2022.12.414

Efficacy and Safety of Subcutaneous Garadacimab for the Prophylaxis of Hereditary Angioedema Attacks in Adults and Adolescent Patients with HAE: Results from a Multicenter, Placebo-Controlled Phase 3 Trial

Timothy J Craig , Gordon Sussman + Show 23 more

Open Access

https://doi.org/10.1016/j.jaci.2022.12.414

Copy DOI

Journal: Journal of Allergy and Clinical Immunology

Publication Date: Feb 1, 2023

#Hereditary Angioedema #Hereditary Angioedema Attacks + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The efficacy and safety of garadacimab, a fully human immunoglobulin G4 monoclonal antibody targeting activated factor XII for the prevention of hereditary angioedema (HAE) attacks, were evaluated in a randomized, placebo-controlled, 6-month, Phase 3 trial (NCT04656418).

Full Text